Myocardial Infarction Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approval by DelveInsight | Faraday Pharma, Acticor Biotech, Boehringer Ingelheim, NuvOx Pharma

Myocardial Infarction pipeline constitutes 30+ key companies continuously working towards developing 40+ Myocardial Infarction treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Myocardial Infarction Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/myocardial-infarction-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myocardial Infarction Market.

The Myocardial Infarction Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Myocardial Infarction Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Myocardial Infarction treatment therapies with a considerable amount of success over the years. Myocardial Infarction Key players such as - Faraday Pharmaceuticals, Acticor Biotech, Boehringer Ingelheim, Novartis, AstraZeneca, Recardio, Idorsia Pharmaceuticals, Eli Lilly and Company, Boehringer Ingelheim, Pfizer, Bayer, Mesoblast, Inc., The Medicines Company, Mitsubishi Tanabe Pharma, Athera Biotechnologies, Hoffmann-La Roche, Idorsia Pharmaceuticals, and others, are developing therapies for the Myocardial Infarction treatment

*
Myocardial Infarction Emerging therapies such as - FDY 5301, Glenzocimab, BI765845, JARDIANCE (empagliflozin), Pelacarsen, FARXIGA(dapagliflozin), Dutogliptin, Selatogrel, abciximab, Empagliflozin, Aliskiren, Eplerenone, Fulacimstat (BAY1142524), Prochymal Registered , Angiomax (bivalirudin) anticoagulant, TNK-tPA, MCC-135, ATH3G10, RO4905417, Selatogrel, and others are expected to have a significant impact on the Myocardial Infarction market in the coming years.

*
Some of the well-established drugs used in the treatment of acute myocardial infarction (AMI) include tenecteplase (TNKASE) by Genentech, evolocumab (REPATHA) by Amgen, and alirocumab (PRALUENT) by Regeneron/Sanofi, among others.

*
In August 2024, CellProthera announced a successful pre-investigational new drug (IND) meeting with the US Food and Drug Administration (FDA), bringing the company closer to launching a pivotal Phase III trial for its cell therapy targeting myocardial infarction. The France-based company stated that the FDA supported the trial design, which includes a two-year follow-up. The trial will assess the therapy's effectiveness in preventing future heart diseases.

*
In July 2024, CellProthera announced the launch of the 'PERFECT' study, a long-term follow-up observational study involving patients from the previous Phase I/IIb EXCELLENT trial. This follows the positive outcomes observed in patients who received ProtheraCytes after experiencing a severe heart attack (acute myocardial infarction) in the initial trial.

*
In June 2024, Faraday Pharmaceuticals announced that it has successfully completed patient enrollment in its ongoing pivotal Phase III Iocyte AMI-3 trial evaluating FDY-5301.

*
In April 2024, The EMPACT-MI phase III clinical trial indicated a 10% relative risk reduction in the primary composite endpoint of time to first hospitalization for heart failure or all-cause mortality for Jardiance Registered (empagliflozin) compared to placebo, although this did not achieve statistical significance. Jardiance was administered to adults within 14 days of an acute myocardial infarction, or heart attack, and showed a reassuring safety profile in this group. Additional pre-specified exploratory analyses revealed a 23% relative risk reduction for the time to first hospitalization due to heart failure and a 33% reduction in total hospitalizations for heart failure with Jardiance versus placebo.

*
In February 2024, Australian CSL announced the topline results from the Phase III AEGIS-II trial of CSL112 in patients after an acute myocardial infarction (MI). The results revealed that the drug did not achieve its primary endpoint of reducing the risk of major adverse cardiovascular events (MACE) within 90 days.

Myocardial Infarction Overview

Myocardial infarction (MI), commonly known as a heart attack, occurs when blood flow to a part of the heart muscle is blocked for an extended period, causing damage or death to the heart tissue. This blockage is typically due to a buildup of fatty deposits, including cholesterol, which form plaques in the coronary arteries. When a plaque ruptures, it can create a clot that obstructs blood flow.

Get a Free Sample PDF Report to know more about Myocardial Infarction Pipeline Assessment-

https://www.delveinsight.com/report-store/myocardial-infarction-pipeline-insight [https://www.delveinsight.com/report-store/myocardial-infarction-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Myocardial Infarction Drugs Under Different Phases of Clinical Development Include:

*
FDY 5301: Faraday Pharmaceuticals

*
Glenzocimab: Acticor Biotech

*
BI765845: Boehringer Ingelheim

*
JARDIANCE (empagliflozin): Boehringer Ingelheim/ Eli Lilly

*
Pelacarsen: Novartis

*
FARXIGA(dapagliflozin): AstraZeneca

*
Dutogliptin: Recardio

*
Selatogrel: Idorsia Pharmaceuticals

*
abciximab: Eli Lilly and Company

*
Empagliflozin: Boehringer Ingelheim

*
Aliskiren: Novartis

*
Eplerenone: Pfizer

*
Fulacimstat (BAY1142524): Bayer

*
Prochymal Registered : Mesoblast, Inc.

*
Angiomax (bivalirudin) anticoagulant: The Medicines Company

*
TNK-tPA: Boehringer Ingelheim

*
MCC-135: Mitsubishi Tanabe Pharma

*
ATH3G10: Athera Biotechnologies

*
RO4905417: Hoffmann-La Roche

*
Selatogrel: Idorsia Pharmaceuticals, and others

Myocardial Infarction Pipeline Therapeutics Assessment

*
Myocardial Infarction Assessment by Product Type

*
Myocardial Infarction By Stage and Product Type

*
Myocardial Infarction Assessment by Route of Administration

*
Myocardial Infarction By Stage and Route of Administration

*
Myocardial Infarction Assessment by Molecule Type

*
Myocardial Infarction by Stage and Molecule Type

DelveInsight's Myocardial Infarction Report covers around 40+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Myocardial Infarction product details are provided in the report. Download the Myocardial Infarction pipeline report to learn more about the emerging Myocardial Infarction therapies [https://www.delveinsight.com/sample-request/myocardial-infarction-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Myocardial Infarction Pipeline Analysis:

The Myocardial Infarction pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the Myocardial Infarction treatment with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myocardial Infarction Treatment.

*
Myocardial Infarction key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Myocardial Infarction Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myocardial Infarction market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Myocardial Infarction drugs and therapies [https://www.delveinsight.com/sample-request/myocardial-infarction-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Myocardial Infarction Pipeline Market Drivers

*
Increasing research and development activities

*
Increasing number of public initiatives and awareness program on cardiovascular disease

Myocardial Infarction Pipeline Market Barriers

*
The lack of emergency care awareness

*
The heterogeneity of patients, along with the duration of treatment and modalities

Scope of Myocardial Infarction Pipeline Drug Insight

*
Coverage: Global

*
Key Myocardial Infarction Companies: Faraday Pharmaceuticals, Acticor Biotech, Boehringer Ingelheim, Novartis, AstraZeneca, Recardio, Idorsia Pharmaceuticals, Eli Lilly and Company, Boehringer Ingelheim, Pfizer, Bayer, Mesoblast, Inc., The Medicines Company, Mitsubishi Tanabe Pharma, Athera Biotechnologies, Hoffmann-La Roche, Idorsia Pharmaceuticals, and others

*
Key Myocardial Infarction Therapies: FDY 5301, Glenzocimab, BI765845, JARDIANCE (empagliflozin), Pelacarsen, FARXIGA(dapagliflozin), Dutogliptin, Selatogrel, abciximab, Empagliflozin, Aliskiren, Eplerenone, Fulacimstat (BAY1142524), Prochymal Registered , Angiomax (bivalirudin) anticoagulant, TNK-tPA, MCC-135, ATH3G10, RO4905417, Selatogrel, and others

*
Myocardial Infarction Therapeutic Assessment: Myocardial Infarction current marketed and Myocardial Infarction emerging therapies

*
Myocardial Infarction Market Dynamics: Myocardial Infarction market drivers and Myocardial Infarction market barriers

Request for Sample PDF Report for Myocardial Infarction Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/myocardial-infarction-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1

Myocardial Infarction Report Introduction

2

Myocardial Infarction Executive Summary

3

Myocardial Infarction Overview

4

Myocardial Infarction- Analytical Perspective In-depth Commercial Assessment

5

Myocardial Infarction Pipeline Therapeutics

6

Myocardial Infarction Late Stage Products (Phase II/III)

7

Myocardial Infarction Mid Stage Products (Phase II)

8

Myocardial Infarction Early Stage Products (Phase I)

9

Myocardial Infarction Preclinical Stage Products

10

Myocardial Infarction Therapeutics Assessment

11

Myocardial Infarction Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Myocardial Infarction Key Companies

14

Myocardial Infarction Key Products

15

Myocardial Infarction Unmet Needs

16

Myocardial Infarction Market Drivers and Barriers

17

Myocardial Infarction Future Perspectives and Conclusion

18

Myocardial Infarction Analyst Views

19

Appendix

20

About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=myocardial-infarction-pipeline-2025-therapies-under-investigation-clinical-trials-milestones-and-fda-approval-by-delveinsight-faraday-pharma-acticor-biotech-boehringer-ingelheim-nuvox-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.